Endoscopy 2022; 54(S 01): S41-S42
DOI: 10.1055/s-0042-1744644
Abstracts | ESGE Days 2022
ESGE Days 2022 Oral presentations
16:30-17:30 Thursday, 28 April 2022 Club E. Post polypectomy and IBD surveillance

STOOL-BASED TESTING TO REDUCE THE NUMBER OF UNNECESSARY SURVEILLANCE COLONOSCOPIES: THE MOCCAS STUDY

B. Carvalho
1   Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, Netherlands
,
W. de Klaver
1   Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, Netherlands
2   Amsterdam UMC Locatie AMC, Amsterdam, Netherlands
,
F. van Wifferen
3   Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands
,
M. van Lanschot
1   Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, Netherlands
2   Amsterdam UMC Locatie AMC, Amsterdam, Netherlands
,
A.J.P. van de Wetering
4   Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands
,
Q.E.W. van der Zander
4   Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands
,
G.M. Lemmens
1   Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, Netherlands
,
A.S. Bolijn
1   Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, Netherlands
,
M. Tijssen
1   Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, Netherlands
,
P. Delis-van Diemen
1   Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, Netherlands
,
N. Buekers
4   Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands
,
K. Daenen
4   Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands
,
J. van der Meer
4   Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands
,
P.G. van Mulligen
1   Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, Netherlands
,
B. Hijmans
1   Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, Netherlands
,
S. de Ridder
2   Amsterdam UMC Locatie AMC, Amsterdam, Netherlands
,
R.W.M. van der Hulst
5   Spaarne Gasthuis, Haarlem, Netherlands
,
J.P. Kuijvenhoven
5   Spaarne Gasthuis, Haarlem, Netherlands
,
A.-M. van Berkel
6   Noordwest Ziekenhuisgroep, Alkmaar, Netherlands
,
A.C.T.M. Depla
7   MC Slotervaart, Amsterdam, Netherlands
,
M.E. van Leerdam
1   Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, Netherlands
,
J.M. Jansen
8   OLVG, Amsterdam, Netherlands
,
C.A. Wientjes
8   OLVG, Amsterdam, Netherlands
,
J.W.A Straathof
9   Maxima Medisch Centrum, Eindhoven, Netherlands
,
E.T.P. Keulen
10   Zuyderland Medisch Centrum, Heerlen, Netherlands
,
D. Ramsoekh
3   Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands
,
L.M.G. Moons
11   Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
,
B.M. Berger
12   EXACT Sciences Corp, Madison, United States
,
G.P. Lidgard
12   EXACT Sciences Corp, Madison, United States
,
M. Zacherl
13   Sysmex-Europe, Norderstedt, Germany
,
A.A.M. Masclee
4   Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands
,
M.J.E. Greuter
3   Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands
,
V.M.H. Coupé
3   Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands
,
M. van Engeland
4   Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands
,
E. Dekker
2   Amsterdam UMC Locatie AMC, Amsterdam, Netherlands
,
G.A. Meijer
1   Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, Netherlands
› Author Affiliations
 

Aims The yield of colonoscopy surveillance after colorectal cancer screening is limited. To lower patient burden and healthcare costs, there is a need to reduce colonoscopies in which no advanced neoplasia is detected. The MOlecular stool testing for Colorectal CAncer Surveillance (MOCCAS) study evaluated whether stool-based testing could safely reduce the number of surveillance colonoscopies.

Methods This cross-sectional study included patients under colonoscopy surveillance, who performed the multi-target stool DNA test (mt-sDNA, Cologuard) and two fecal immunochemical tests (FITs, OC-Sensor and FOB-Gold) before colonoscopy. Test characteristics were determined for all stool tests. With the validated Adenoma and Serrated pathway to Colorectal CAncer (ASCCA) model, we simulated a colonoscopy surveillance (European post-polypectomy surveillance guideline) strategy and stool-based surveillance strategies that varied in stool-based test and test interval. We chose test cut-offs such that predicted effectiveness (colorectal cancer mortality) of stool-based surveillance equaled effectiveness of colonoscopy surveillance. Outcomes of each strategy included number of colonoscopies and costs.

Results 3453 Patients had a valid result for all stool tests and a complete colonoscopy. Colonoscopy surveillance was predicted to result in 1669 lifetime colonoscopies per 1000 individuals under surveillance. At equal effectiveness, fewer colonoscopies were predicted for all stool-based strategies (16-41% reduction). Annual testing with FOB-Gold led to the largest reduction in colonoscopies (41%, cut-off≥32 µg/g). Mt-sDNA surveillance was more costly than colonoscopy surveillance, while FIT-based surveillance saved costs.

Conclusions Stool-based surveillance can be as effective as post-polypectomy colonoscopy surveillance, and reduces the number of colonoscopies by up to 41% without increasing healthcare costs.



Publication History

Article published online:
14 April 2022

© 2022. European Society of Gastrointestinal Endoscopy. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany